Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MYNZ 
Mainz Biomed BV (MYNZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: MYNZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.27% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.90M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 2 | Beta 0.26 | 52 Weeks Range 0.92 - 8.20 | Updated Date 11/22/2025 |
52 Weeks Range 0.92 - 8.20 | Updated Date 11/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.28 |
Earnings Date
Report Date 2025-11-28 | When - | Estimate -2 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2822.06% |
Management Effectiveness
Return on Assets (TTM) -114.35% | Return on Equity (TTM) -465.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11139907 | Price to Sales(TTM) 15.22 |
Enterprise Value 11139907 | Price to Sales(TTM) 15.22 | ||
Enterprise Value to Revenue 16.88 | Enterprise Value to EBITDA -2.84 | Shares Outstanding 5412853 | Shares Floating 3506432 |
Shares Outstanding 5412853 | Shares Floating 3506432 | ||
Percent Insiders 1.38 | Percent Institutions 6.91 |
Upturn AI SWOT
Mainz Biomed BV
Company Overview
History and Background
Mainz Biomed BV focuses on developing and commercializing innovative molecular genetic diagnostic solutions for life-threatening conditions. It was founded in 2007. Its evolution includes focusing on colorectal cancer detection through non-invasive methods.
Core Business Areas
- Colorectal Cancer Diagnostics: Development and commercialization of colorectal cancer screening tests, primarily focusing on non-invasive detection methods using stool samples.
- Research and Development: Ongoing research and development efforts to improve the accuracy and expand the applications of their diagnostic technologies.
Leadership and Structure
Guido Baechler is the CEO. The company operates with a typical hierarchical structure for a biotech firm, with departments dedicated to R&D, commercialization, and operations.
Top Products and Market Share
Key Offerings
- ColoAlert: ColoAlert is a non-invasive, easy-to-use screening test for early detection of colorectal cancer using stool DNA analysis. Market share data is difficult to pinpoint exactly for ColoAlert, but the overall market for colorectal cancer screening is substantial and growing. Competitors include Exact Sciences (EXAS) with Cologuard, and other traditional screening methods like colonoscopy.
Market Dynamics
Industry Overview
The industry focuses on early cancer detection through advanced diagnostics. This includes molecular diagnostics, genomics, and personalized medicine. It is growing rapidly due to increasing awareness, technological advancements, and the need for cost-effective screening solutions.
Positioning
Mainz Biomed is positioned as a player in the non-invasive colorectal cancer screening market, competing with established players like Exact Sciences. Their competitive advantage lies in their proprietary technology and the potential for improved accuracy and ease of use.
Total Addressable Market (TAM)
The global colorectal cancer diagnostics market is expected to reach billions of USD. Mainz Biomed's positioning in the non-invasive screening segment targets a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary technology in stool DNA analysis
- Non-invasive and easy-to-use screening tests
- Potential for early cancer detection and improved patient outcomes
- Strong focus on research and development
Weaknesses
- Limited market share compared to established competitors
- Dependence on regulatory approvals and reimbursement
- Financial resources relative to larger competitors
- Relatively small commercial infrastructure
Opportunities
- Expanding market for non-invasive cancer screening
- Increasing awareness and adoption of early detection methods
- Potential for partnerships and collaborations
- Expansion into new geographic markets
- FDA approval pathway to gain access to the US market
Threats
- Competition from established players with greater resources
- Technological advancements that could render their technology obsolete
- Changes in regulatory landscape and reimbursement policies
- Clinical trial outcomes not meeting expectations
Competitors and Market Share
Key Competitors
- EXAS
Competitive Landscape
Mainz Biomed faces significant competition from Exact Sciences (EXAS) and other players in the colorectal cancer screening market. Mainz Biomed's success depends on demonstrating the superior performance and cost-effectiveness of its ColoAlert test.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are dependent on revenue and profit figures, which are not available in this limited dataset.
Future Projections: Future growth projections are based on analyst estimates, which can be obtained from financial news and investment research platforms.
Recent Initiatives: Recent initiatives include progress in ColoAlert clinical studies, focusing on U.S. market entry.
Summary
Mainz Biomed is a developing company focused on colorectal cancer screening. ColoAlert is their primary product, targeting a growing market. Their weaknesses include competition and limited resources, but they have opportunities for growth through strategic partnerships and market expansion. The US market is important to the future of Mainz Biomed.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Financial News Sources
Disclaimers:
This analysis is based on limited publicly available information. Investment decisions should be based on thorough research and professional financial advice. Market share data are approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mainz Biomed BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-05 | CEO & Executive Director Mr. Guido Baechler | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 19 | Website https://mainzbiomed.com |
Full time employees 19 | Website https://mainzbiomed.com | ||
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.